Drilldown: Medicines
Appearance
Medicines > classes
:
Neuroleptic
or
Phenethylamine
or
[[:Category:Sympathomimetics|Sympathomimetic (indirect-acting)]] 
:
Neuroleptic
or
Phenethylamine
or
[[:Category:Sympathomimetics|Sympathomimetic (indirect-acting)]] 
Use the filters below to narrow your results.
generic:
None (25) ·
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Orap (1) ·
Prolixin (1) ·
Saphris (1) ·
Stelazine (1) ·
Sudafed (IR, 12-hour, 24-hour); many combination products including Claritin-D, Allegra-D, Zyrtec-D, Mucinex-D (1) ·
Thorazine (1) ·
Trilafon (1)
None (1) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Thioxanthene D2 antagonist (1) ·
Very potent 5-HT2A agonist; long duration (1)
None (40) ·
Not established (1) ·
Some controversial signal for first-trimester gastroschisis association in observational studies; limited use is generally considered acceptable after the first trimester.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (40) ·
'''[[USLegal:Behind-the-counter|Behind-the-counter]] in US''' under the Combat Methamphetamine Epidemic Act 2005: purchase restricted to ≤3.6 g/day and ≤9 g/30 days, with photo ID, logbook signature, and quantity logging required. Several states schedule higher than federal (1) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1)
Showing below up to 42 results in range #1 to #42.

